Citation Impact
Citing Papers
Polo-like Kinase 3 Functions as a Tumor Suppressor and Is a Negative Regulator of Hypoxia-Inducible Factor-1α under Hypoxic Conditions
2008
INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors
2007
EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early C. elegans embryo
2007
Polo-like Kinase 1 Facilitates Loss of Pten Tumor Suppressor-induced Prostate Cancer Formation
2011
Comprehensive genomic characterization of head and neck squamous cell carcinomas
2015 StandoutNature
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8
2016
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis
2012
Head and neck squamous cell carcinoma
2020 Standout
Plk1-mediated Phosphorylation of Topors Regulates p53 Stability
2009
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells
2002
Regulation of PTEN Stability and Activity by Plk3
2010
Nutraceuticals: Facts and fiction
2007 Standout
Getting in and out of mitosis with Polo-like kinase-1
2005
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition
2010 Standout
Spermatogenesis in fish
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Transcriptional analysis of testis maturation using trout cDNA macroarrays
2005
Medicinal properties of mangosteen (Garcinia mangostana)
2008 Standout
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
2006
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
2004 StandoutNature
The Spliceosome: Design Principles of a Dynamic RNP Machine
2009 Standout
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor
2011
Delivery materials for siRNA therapeutics
2013 Standout
SWI/SNF nucleosome remodellers and cancer
2011 Standout
Naturally occurring B-cell responses to breast cancer
2003
Tumor inhibition by genomically integrated inducible RNAi-cassettes
2006
Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism
2016 Standout
Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells
2005
Polo on the Rise—from Mitotic Entry to Cytokinesis with Plk1
2008
Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73
2015
Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations
2009 Standout
Aptamers as therapeutics
2010 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
The dark side of a tumor suppressor: anti-apoptotic p53
2008
Some p53-binding proteins that can function as arbiters of life and death
2006
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53
2013
Up-regulation of tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 in human colon cancer Caco-2 cells following repetitive exposure to dietary levels of a polyphenol-rich chokeberry juice
2006
The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease
2007
Expression of Polo-Like Kinase 1 (PLK1) Protein Predicts the Survival of Patients with Gastric Carcinoma
2006
p53 in health and disease
2007 Standout
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
2014
GSK-3β Targets Cdc25A for Ubiquitin-Mediated Proteolysis, and GSK-3β Inactivation Correlates with Cdc25A Overproduction in Human Cancers
2008
Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells
2012
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
2013
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules
2014
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Knocking down barriers: advances in siRNA delivery
2009 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Targeting polo-like kinase 1 for cancer therapy
2006
Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions
2008
Identification of common or distinct genes related to antitumor activities of a medicinal herb and its major component by oligonucleotide microarray
2003
Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy
2007
Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway
2012
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
pERK 1/2 inhibit Caspase‐8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner
2013
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
The spindle-assembly checkpoint in space and time
2007 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
2009
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors
2005
Natural Polyphenols for Prevention and Treatment of Cancer
2016 Standout
Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
2015
Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
2018
Transcriptional control of human p53-regulated genes
2008 Standout
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
2010
Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome
2004 StandoutNobel
TCTP in Development and Cancer
2012 StandoutNobel
The cytoskeleton and cancer
2009
SCF/β-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner
2011 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Flavonoids in Cancer and Apoptosis
2018 Standout
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells
2017
Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells
2003
Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis
2010
Caspase‐8: regulating life and death
2017 Standout
Works of Frank Eckerdt being referenced
Polo-like kinases and oncogenesis
2005
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1
2002
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells
2004
Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells
2005
Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation.
2002
Polo-Like Kinase 1: Target and Regulator of Anaphase-Promoting Complex/Cyclosome–Dependent Proteolysis
2006
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition
2016